YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agr...
* Co-development of innovative new drug for the treatment of Fabry disease as "the world's first ...
* Newly established R&D division this year is expected to provide full-scale in-house R&D in addi...
* FDA's Fast Track designation speeds up the development of new biologic drugs for rare diseases ...
YONGIN, South Korea, June 5, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics comp...
YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 S...
* Introduced the first ddPCR device in Korea to provide high-quality clinical trial sample analys...
YONGIN, South Korea, May 21, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have a...
YONGIN, South Korea, May 20, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma announ...
YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics compa...
Offering Hope for Enhanced Early Detection and Patient Care in the Battle Against Cancer YONGIN, S...
* Recent updates on its development of LSD treatments were presented YONGIN, South Korea, Feb. 14...
YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that th...
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces th...
* To commence operation by 2027…with max. 400K liters of plasma production capacity per annum *...
* Completed the construction of a GMP pilot plant in its Hwasun production plant in Jeollanam-do,...
Recognized for its global-quality sample analysis services based on various analytical platforms Y...
- Collaboration includes the transfer of GC Genome's essential wet lab know-how for SNP genotyping ...
YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has ap...
Brining Expertise in NK Cell Therapy to Advance Efforts in Cancer Prevention, early detection, and ...